Whole-body MRI: review of MET-RADS, MY-RADS and ONCO-RADS
6th July, 2025 1:00 PM
London
Online
Prof. Anwar Padhani
Secure your spot at this conference
Overview
Introduction
Whole-body MRI plays a crucial role in oncological imaging, providing comprehensive assessments of metastatic disease, multiple myeloma, and tumor response. Standardized reporting frameworks like MET-RADS, MY-RADS, and ONCO-RADS enhance consistency and accuracy in interpretation, aiding clinical decision-making.
Main Content
- MET-RADS: Standardized criteria for assessing metastatic disease burden and treatment response.
- MY-RADS: A structured approach for imaging and monitoring multiple myeloma.
- ONCO-RADS: Guidelines for whole-body MRI evaluation of oncological conditions and response assessment.
Conclusion
A structured and standardized approach to whole-body MRI, using MET-RADS, MY-RADS, and ONCO-RADS, improves diagnostic accuracy, facilitates clinical decision-making, and enhances patient outcomes in oncologic imaging.
Learning Objectives
- Understand the Role of Whole-Body MRI: Learn how whole-body MRI is utilized for comprehensive oncological assessment, including metastatic disease, multiple myeloma, and tumor response evaluation.
- Familiarize with Standardized Reporting Systems: Gain insights into the MET-RADS, MY-RADS, and ONCO-RADS frameworks to improve consistency, accuracy, and clinical relevance in radiological reporting.
- Enhance Clinical Application and Decision-Making: Recognize how these standardized imaging criteria support treatment planning, disease monitoring, and personalized patient management in oncology.
London
The authors of MET-RADS, MY-RADS and ONCO-RADS present and discuss current and future status of WB-MRI. Free to watch live, then available to watch retrospectively in the Members \' area of the ICIS website.
Registration Fees
This is a free event
Accreditation
Royal College of Radiologists accreditation has been applied for.
